Osteoporosis Drugs Market Analysis By Product (Branded, Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), Rank Ligand Inhibitors, Generics), And Segment Forecasts, 2014 - 2025

The global osteoporosis drugs market is expected to reach USD 16.3 billion by 2025, according to a new study by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Further key findings from the study suggest:

Branded drugs held the dominant share of the product segment in 2015. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy

Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies

In 2015, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics

Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care

The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market summary
Chapter 3 Osteoporosis Drugs Market Variables, Trends & Scope
3.1 Market segmentation& scope
3.1.1 Market Driver Analysis
3.1.2 Market Restraint Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Osteoporosis Drugs - SWOT Analysis
3.4 Industry Analysis - Porter’s
3.5 Product Pipeline Analysis
3.6 Company Market Share, 2015
Chapter 4 Osteoporosis Drugs Product Estimates & Trend Analysis
4.1 Osteoporosis Drugs Market: Product Movement Analysis
4.2 Branded
4.2.1 Branded market, 2014 - 2025 (USD Million)
4.2.2 Bisphosphonates
4.2.2.1 Bisphosphonates market, 2014 - 2025 (USD Million)
4.2.3 Parathyroid Hormone Therapy
4.2.3.1 Parathyroid hormone therapy market, 2014 - 2025 (USD Million)
4.2.4 Calcitonin
4.2.4.1 Calcitonin market, 2014 - 2025 (USD Million)
4.2.5 Selective Estrogen Inhibitors Modulator (SERM)
4.2.5.1 SERM market, 2014 - 2025 (USD Million)
4.2.6 Rank Ligand Inhibitors
4.2.6.1 Rank ligand Inhibitors market, 2014 - 2025 (USD Million)
4.2.7 Others
4.2.7.1 Others market, 2014 - 2025 (USD Million)
4.3 Generic
4.3.1 Generic market, 2014 - 2025 (USD Million)
Chapter 5 Osteoporosis Drugs Regional Estimates & Trend Analysis, by Product
5.1 Osteoporosis drugs market share by region, 2015 & 2025
5.2 North America
5.2.1 North America osteoporosis drugs market, 2014 - 2025 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. osteoporosis drugs market, 2014 - 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Canada osteoporosis drugs market, 2014 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe osteoporosis drugs market, 2014 - 2025 (USD Million)
5.3.2 UK
5.3.2.1 UK osteoporosis drugs market, 2014 - 2025 (USD Million)
5.3.3 Germany
5.3.3.1 Germany osteoporosis drugs market, 2014 - 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific osteoporosis drugs market, 2014 - 2025 (USD Million)
5.4.2 Japan
5.4.2.1 Japan osteoporosis drugs market, 2014 - 2025 (USD Million)
5.4.3 China
5.4.3.1 China osteoporosis drugs market, 2014 - 2025 (USD Million)
5.4.4 India
5.4.4.1 India osteoporosis drugs market, 2014 - 2025 (USD Million)
5.5 Latin America
5.5.1 Latin America osteoporosis drugs market, 2014 - 2025 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil osteoporosis drugs market, 2014 - 2025 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico osteoporosis drugs market, 2014 - 2025 (USD Million)
5.6 MEA
5.6.1 MEA osteoporosis drugs market, 2014 - 2025 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa osteoporosis drugs market, 2014 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy framework
6.2 Market participation categorization
6.3 Company Profiles
6.3.1 Pfizer, Inc.
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Geographic Foothold
6.3.1.4 Product benchmarking
6.3.1.5 Strategic initiatives
6.3.2 F.Hoffmann La Roche
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Geographic Foothold
6.3.2.4 Product benchmarking
6.3.2.5 Strategic initiatives
6.3.3 Teva Pharmaceuticals
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Geographic Foothold
6.3.3.4 Product benchmarking
6.3.4 Novartis AG
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 Geographic Foothold
6.3.4.4 Product benchmarking
6.3.4.5 Strategic initiatives
6.3.5 Merck & Co AG
6.3.5.1 Company overview
6.3.5.2 Financial Performance
6.3.5.3 Geographic Foothold
6.3.5.4 Product benchmarking
6.3.5.5 Strategic initiatives
6.3.6 Amgen, Inc.
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 Geographic Foothold
6.3.6.4 Product benchmarking
6.3.6.5 Strategic initiatives
6.3.7 Allergan plc
6.3.7.1 Company overview
6.3.7.2 Financial performance
6.3.7.3 Geographic Foothold
6.3.7.4 Product benchmarking
6.3.7.5 Strategic initiatives
6.3.8 GlaxoSmithKline
6.3.8.1 Company overview
6.3.8.2 Financial performance
6.3.8.3 Geographic Foothold
6.3.8.4 Product benchmarking
6.3.8.5 Strategic initiatives
6.3.9 Eli Lilly and Company
6.3.9.1 Company overview
6.3.9.2 Financial performance
6.3.9.3 Geographic Foothold
6.3.9.4 Product Benchmarking
6.3.9.5 Strategic initiatives